The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Jun 7

PMID 34095111

Citations 58

Authors

Yanghong Ni

Xiaoting Zhou

Jia Yang

Houhui Shi

Hongyi Li

Xia Zhao

Xuelei Ma

Affiliations

Soon will be listed here.

Abstract

Cancer cells resistance to various therapies remains to be a key challenge nowadays. For a long time, scientists focused on tumor cells themselves for the mechanisms of acquired drug resistance. However, recent evidence showed that tumor microenvironment (TME) is essential for regulating immune escape, drug resistance, progression and metastasis of malignant cells. Reciprocal interactions between cancer cells and non-malignant cells within this milieu often reshape the TME and promote drug resistance. Therefore, advanced knowledge about these sophisticated interactions is significant for the design of effective therapeutic approaches. In this review, we highlight cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), T-regulatory lymphocytes (Tregs), mesenchymal stem cells (MSCs), cancer-associated adipocytes (CAAs), and tumor endothelial cells (TECs) existing in TME, as well as their multiple cross-talk with tumor cells, which eventually endows tumor cells with therapeutic resistance.

Citing Articles

Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance.

Xiao Y, Hassani M, Moghaddam M, Fazilat A, Ojarudi M, Valilo M Med Oncol. 2025; 42(4):108.

PMID: 40087196 DOI: 10.1007/s12032-025-02675-8.

Exploration of crucial stromal risk genes associated with prognostic significance and chemotherapeutic opportunities in invasive ductal breast carcinoma.

Tang G, Wang Z, Geng W, Yu Y, Zhang Y J Genet Eng Biotechnol. 2025; 23(1):100448.

PMID: 40074422 PMC: 11732444. DOI: 10.1016/j.jgeb.2024.100448.

Modeling critical dosing strategies for stromal-induced resistance to cancer therapy.

Kraut A, Garvey C, Strelez C, Mumenthaler S, Foo J NPJ Syst Biol Appl. 2025; 11(1):16.

PMID: 39915486 PMC: 11802896. DOI: 10.1038/s41540-025-00495-0.

Comprehensive Transcriptomic Analysis Reveals Cell-Type-Specific Roles of Human Odorant Receptors in Glioblastoma and the Tumor Microenvironment.

Cho H, Yeo D, Yang H, Koo J Int J Mol Sci. 2025; 25(24.

PMID: 39769144 PMC: 11676228. DOI: 10.3390/ijms252413382.

Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.

Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y Mol Cancer. 2024; 23(1):261.

PMID: 39574178 PMC: 11580516. DOI: 10.1186/s12943-024-02165-x.

References

Teng F, Tian W, Wang Y, Zhang Y, Guo F, Zhao J . Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol. 2016; 9:8. PMC: 4744391. DOI: 10.1186/s13045-015-0231-4. View

Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth E, Watson K . Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy. 2010; 12(5):615-25. DOI: 10.3109/14653241003631815. View

Long Y, Tao H, Karachi A, Grippin A, Jin L, Chang Y . Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Res. 2019; 80(3):499-509. DOI: 10.1158/0008-5472.CAN-19-1577. View

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M . IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018; 559(7714):363-369. PMC: 6461206. DOI: 10.1038/s41586-018-0266-0. View

Yu W, Cao D, Li Q, Mei H, Hu Y, Guo T . Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy. Oncotarget. 2016; 7(52):86075-86086. PMC: 5349898. DOI: 10.18632/oncotarget.13342. View

Yin Z, Jiang K, Li R, Dong C, Wang L . Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy. Mol Cancer. 2018; 17(1):178. PMC: 6309092. DOI: 10.1186/s12943-018-0926-6. View

Liu S, Lee J, Jie C, Park M, Iwakura Y, Patel Y . HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance. Cancer Res. 2018; 78(8):2040-2051. PMC: 5899630. DOI: 10.1158/0008-5472.CAN-17-2761. View

Mohamed E, Sierra R, Trillo-Tinoco J, Cao Y, Innamarato P, Payne K . The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020; 52(4):668-682.e7. PMC: 7207019. DOI: 10.1016/j.immuni.2020.03.004. View

Kim S, Woo J, Jeong C, Ryu C, Lim J, Jeun S . Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. Cancer Res. 2012; 72(18):4807-17. DOI: 10.1158/0008-5472.CAN-12-0123. View

10.

Zhang X, Chen Y, Hao L, Hou A, Chen X, Li Y . Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine. Cancer Lett. 2016; 381(2):305-13. DOI: 10.1016/j.canlet.2016.08.004. View

11.

Bani M, Decio A, Giavazzi R, Ghilardi C . Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. Angiogenesis. 2017; 20(2):233-241. DOI: 10.1007/s10456-017-9549-6. View

12.

Li C, Yang W, Gai X, Zhang Y, Li Y, Fu H . Foxp3 overexpression decreases sensitivity to chemotherapy in mouse Lewis lung cancer cells. Mol Med Rep. 2012; 6(5):977-82. DOI: 10.3892/mmr.2012.1066. View

13.

Wang J, Liu X, Qiu Y, Shi Y, Cai J, Wang B . Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2018; 11(1):11. PMC: 5778754. DOI: 10.1186/s13045-018-0554-z. View

14.

Ma J, Song X, Xu X, Mou Y . Cancer-Associated Fibroblasts Promote the Chemo-resistance in Gastric Cancer through Secreting IL-11 Targeting JAK/STAT3/Bcl2 Pathway. Cancer Res Treat. 2018; 51(1):194-210. PMC: 6333970. DOI: 10.4143/crt.2018.031. View

15.

Liu Y, Cao X . The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2014; 12(1):1-4. PMC: 4654376. DOI: 10.1038/cmi.2014.83. View

16.

Zeng J, Chen S, Li C, Ye Z, Lin B, Liang Y . Mesenchymal stem/stromal cells-derived IL-6 promotes nasopharyngeal carcinoma growth and resistance to cisplatin via upregulating CD73 expression. J Cancer. 2020; 11(8):2068-2079. PMC: 7052921. DOI: 10.7150/jca.37932. View

17.

Muller C . Tumour-surrounding adipocytes are active players in breast cancer progression. Ann Endocrinol (Paris). 2013; 74(2):108-10. DOI: 10.1016/j.ando.2013.02.007. View

18.

Pistore C, Giannoni E, Colangelo T, Rizzo F, Magnani E, Muccillo L . DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells. Oncogene. 2017; 36(40):5551-5566. DOI: 10.1038/onc.2017.159. View

19.

Zeisberg E, Potenta S, Xie L, Zeisberg M, Kalluri R . Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007; 67(21):10123-8. DOI: 10.1158/0008-5472.CAN-07-3127. View

20.

Kim H, Jung M, Choi S, Woo J, Piao Y, Hwang E . IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression. J Exp Clin Cancer Res. 2018; 37(1):200. PMC: 6106749. DOI: 10.1186/s13046-018-0867-3. View